Phase I Clinical Study, Evaluating Safety and Tolerability of PRO-232 an Ophthalmic Solution, Versus Placebo, When Applied to the Ocular Surface of Ophthalmologically and Clinically Healthy Volunteers.
Latest Information Update: 15 Apr 2024
At a glance
- Drugs Moxifloxacin/dexamethasone (Primary)
- Indications Inflammation
- Focus Adverse reactions
- Sponsors Laboratorios Sophia
- 15 Apr 2024 New trial record